2,699 Shares in LeMaitre Vascular, Inc. $LMAT Purchased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC bought a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,699 shares of the medical instruments supplier’s stock, valued at approximately $224,000.

A number of other large investors also recently modified their holdings of LMAT. Principal Financial Group Inc. raised its holdings in shares of LeMaitre Vascular by 3.0% in the 1st quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier’s stock worth $9,385,000 after purchasing an additional 3,248 shares during the period. Envestnet Asset Management Inc. raised its holdings in shares of LeMaitre Vascular by 9.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 285,109 shares of the medical instruments supplier’s stock worth $23,921,000 after purchasing an additional 25,680 shares during the period. Linden Thomas Advisory Services LLC raised its holdings in shares of LeMaitre Vascular by 3.2% in the 1st quarter. Linden Thomas Advisory Services LLC now owns 35,591 shares of the medical instruments supplier’s stock worth $2,986,000 after purchasing an additional 1,109 shares during the period. Alps Advisors Inc. purchased a new position in shares of LeMaitre Vascular in the 1st quarter worth about $354,000. Finally, Mutual of America Capital Management LLC raised its holdings in shares of LeMaitre Vascular by 6.1% in the 1st quarter. Mutual of America Capital Management LLC now owns 35,331 shares of the medical instruments supplier’s stock worth $2,964,000 after purchasing an additional 2,038 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $89.21 on Friday. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The business has a 50 day moving average price of $91.31 and a two-hundred day moving average price of $86.77. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The firm has a market cap of $2.02 billion, a PE ratio of 43.31, a price-to-earnings-growth ratio of 2.30 and a beta of 0.77.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm had revenue of $63.15 million during the quarter, compared to analyst estimates of $62.48 million. During the same quarter last year, the firm earned $0.52 EPS. LeMaitre Vascular’s quarterly revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 38.83%.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 10,815 shares of the stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.39, for a total transaction of $999,197.85. Following the transaction, the director owned 17,976 shares of the company’s stock, valued at $1,660,802.64. This trade represents a 37.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John A. Roush sold 6,561 shares of the stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the transaction, the director directly owned 2,916 shares in the company, valued at approximately $269,875.80. This represents a 69.23% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 120,815 shares of company stock worth $11,280,206. 9.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LMAT. Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Saturday. Barrington Research restated an “outperform” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Finally, Cantor Fitzgerald raised their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $97.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.